Clinical Trials Browser

Phase 1 × Rifaximin × 90 days × Clear all

NCT03820817 2026-05-26

Rifaximin in Patients With Monoclonal Gammopathy

Phase 1 Completed

Waldenstrom Macroglobulinemia, Paraproteinemias